Xenon Pharmaceuticals Inc... (XENE)
| Bid | 29.4 |
| Market Cap | 2.41B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -10.45 |
| Forward PE | -11.04 |
| Analyst | Buy |
| Ask | 36.74 |
| Volume | 1,011,077 |
| Avg. Volume (20D) | 458,820 |
| Open | 30.42 |
| Previous Close | 30.64 |
| Day's Range | 30.24 - 32.17 |
| 52-Week Range | 30.21 - 46.00 |
| Beta | 1.26 |
About XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...
Analyst Forecast
According to 8 analyst ratings, the average rating for XENE stock is "Buy." The 12-month stock price forecast is $57.5, which is an increase of 82.83% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call TranscriptXenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President a...
2 months ago · seekingalpha.com
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy PotentialXenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should las...